272 Citations (Scopus)

Abstract

Lymphomas are solid tumours of the immune system. Hodgkin's lymphoma accounts for about 10% of all lymphomas, and the remaining 90% are referred to as non-Hodgkin lymphoma. Non-Hodgkin lymphomas have a wide range of histological appearances and clinical features at presentation, which can make diagnosis difficult. Lymphomas are not rare, and most physicians, irrespective of their specialty, will probably have come across a patient with lymphoma. Timely diagnosis is important because effective, and often curative, therapies are available for many subtypes. In this Seminar we discuss advances in the understanding of the biology of these malignancies and new, available treatments.

Original languageEnglish (US)
Pages (from-to)848-857
Number of pages10
JournalThe Lancet
Volume380
Issue number9844
DOIs
StatePublished - Sep 2012

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Hodgkin Disease
Immune System
Neoplasms
Physicians
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012). Non-Hodgkin lymphoma. The Lancet, 380(9844), 848-857. https://doi.org/10.1016/S0140-6736(12)60605-9

Non-Hodgkin lymphoma. / Shankland, Kate R.; Armitage, James Olen; Hancock, Barry W.

In: The Lancet, Vol. 380, No. 9844, 09.2012, p. 848-857.

Research output: Contribution to journalReview article

Shankland, KR, Armitage, JO & Hancock, BW 2012, 'Non-Hodgkin lymphoma', The Lancet, vol. 380, no. 9844, pp. 848-857. https://doi.org/10.1016/S0140-6736(12)60605-9
Shankland, Kate R. ; Armitage, James Olen ; Hancock, Barry W. / Non-Hodgkin lymphoma. In: The Lancet. 2012 ; Vol. 380, No. 9844. pp. 848-857.
@article{242e7ebe529345299a94824f9297f6c9,
title = "Non-Hodgkin lymphoma",
abstract = "Lymphomas are solid tumours of the immune system. Hodgkin's lymphoma accounts for about 10{\%} of all lymphomas, and the remaining 90{\%} are referred to as non-Hodgkin lymphoma. Non-Hodgkin lymphomas have a wide range of histological appearances and clinical features at presentation, which can make diagnosis difficult. Lymphomas are not rare, and most physicians, irrespective of their specialty, will probably have come across a patient with lymphoma. Timely diagnosis is important because effective, and often curative, therapies are available for many subtypes. In this Seminar we discuss advances in the understanding of the biology of these malignancies and new, available treatments.",
author = "Shankland, {Kate R.} and Armitage, {James Olen} and Hancock, {Barry W.}",
year = "2012",
month = "9",
doi = "10.1016/S0140-6736(12)60605-9",
language = "English (US)",
volume = "380",
pages = "848--857",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9844",

}

TY - JOUR

T1 - Non-Hodgkin lymphoma

AU - Shankland, Kate R.

AU - Armitage, James Olen

AU - Hancock, Barry W.

PY - 2012/9

Y1 - 2012/9

N2 - Lymphomas are solid tumours of the immune system. Hodgkin's lymphoma accounts for about 10% of all lymphomas, and the remaining 90% are referred to as non-Hodgkin lymphoma. Non-Hodgkin lymphomas have a wide range of histological appearances and clinical features at presentation, which can make diagnosis difficult. Lymphomas are not rare, and most physicians, irrespective of their specialty, will probably have come across a patient with lymphoma. Timely diagnosis is important because effective, and often curative, therapies are available for many subtypes. In this Seminar we discuss advances in the understanding of the biology of these malignancies and new, available treatments.

AB - Lymphomas are solid tumours of the immune system. Hodgkin's lymphoma accounts for about 10% of all lymphomas, and the remaining 90% are referred to as non-Hodgkin lymphoma. Non-Hodgkin lymphomas have a wide range of histological appearances and clinical features at presentation, which can make diagnosis difficult. Lymphomas are not rare, and most physicians, irrespective of their specialty, will probably have come across a patient with lymphoma. Timely diagnosis is important because effective, and often curative, therapies are available for many subtypes. In this Seminar we discuss advances in the understanding of the biology of these malignancies and new, available treatments.

UR - http://www.scopus.com/inward/record.url?scp=84865590950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865590950&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(12)60605-9

DO - 10.1016/S0140-6736(12)60605-9

M3 - Review article

C2 - 22835603

AN - SCOPUS:84865590950

VL - 380

SP - 848

EP - 857

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9844

ER -